We are live on
!
Find out more
FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$237M
1-Year Est. Return
107.53%
This Fund
S&P 500
This Quarter
Est. Return
+57.38%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$278M
AUM Growth
+$60.4M
(+28%)
Cap. Flow
-$21.3M
Cap. Flow
% of AUM
-7.67%
Top 10 Holdings %
Top 10 Hldgs %
88.48%
Holding
20
New
2
Increased
3
Reduced
6
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alector
ALEC
|
+$22.8M |
| 2 |
Cytokinetics
CYTK
|
+$11.4M |
| 3 |
OPTN
OptiNose
OPTN
|
+$5.56M |
| 4 |
Voyager Therapeutics
VYGR
|
+$2.32M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
+$144K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$14.6M |
| 2 |
Insmed
INSM
|
+$11.5M |
| 3 |
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
|
+$10.5M |
| 4 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
+$5.94M |
| 5 |
Aclaris Therapeutics
ACRS
|
+$5.53M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$22.4B
| $44.6M | 16.02% |
1,533,883
-443,353
| -22% | -$11.5M |
|
|
CBAY
2
DELISTED
Cymabay Therapeutics
CBAY
| $34.9M | 12.56% |
2,631,258
| – | – |
|
3
Ascendis Pharma A/S
ASND
$16.5B
| $28.9M | 10.38% |
245,424
| – | – |
|
|
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $26.7M | 9.59% |
518,560
-337,340
| -39% | -$14.6M |
|
|
OPTN
5
DELISTED
OptiNose
OPTN
| $25M | 8.99% |
161,827
+47,924
| +42% | +$5.56M |
|
|
IMMU
6
DELISTED
Immunomedics Inc
IMMU
| $22.3M | 8.02% |
1,161,965
-43,398
| -4% | -$699K |
|
|
MYOK
7
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $20M | 7.19% |
384,993
-101,631
| -21% | -$4.68M |
|
8
Replimune Group
REPL
$454M
| $18.7M | 6.73% |
1,229,656
| – | – |
|
|
9
Cytokinetics
CYTK
$10.6B
| $13.9M | 5.01% |
1,723,170
+1,548,022
| +884% | +$11.4M |
|
|
10
Rhythm Pharmaceuticals
RYTM
$7.31B
| $11.1M | 3.99% |
405,026
+5,026
| +1% | +$144K |
|
|
11
Alector
ALEC
$169M
| $10.7M | 3.84% |
+1,203,462
| New | +$22.8M |
|
|
AERI
12
DELISTED
Aerie Pharmaceuticals
AERI
| $10.1M | 3.62% |
211,823
-50,000
| -19% | -$2.2M |
|
13
SI-BONE Inc
SIBN
$818M
| $3.87M | 1.39% |
205,621
| – | – |
|
|
14
Voyager Therapeutics
VYGR
$181M
| $3.4M | 1.22% |
+177,804
| New | +$2.32M |
|
15
Arbutus Biopharma
ABUS
$847M
| $2.88M | 1.04% |
804,446
-777,829
| -49% | -$2.99M |
|
16
Kiniksa Pharmaceuticals
KNSA
$6.23B
| $1.15M | 0.41% |
63,922
| – | – |
|
|
17
Aclaris Therapeutics
ACRS
$715M
| – | – |
-748,132
| Closed | -$5.53M |
|
|
ORTX
18
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| – | – |
-66,836
| Closed | -$10.5M |
|
|
EIDX
19
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| – | – |
-431,781
| Closed | -$5.94M |
|
|
PTLA
20
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-250,000
| Closed | -$4.88M |
|
Similar funds
BCM
ICMM
AG
FL
EA
PVM
MFA
TCM
Foresite Capital Management IV's Q1 2019 Portfolio in Review
As of Q1 2019, Foresite Capital Management IV held 20 positions worth $278M, up 28% from $218M the previous quarter. Its ten largest holdings account for 88% of the portfolio.
Foresite Capital Management IV withdrew a net $21.3M in Q1 2019, closing 4 positions and reducing 6 holdings. Its most notable exit was Orchard Therapeutics plc American Depositary Shares, an estimated $10.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier.
Against the trend, Foresite Capital Management IV opened a new position in Alector worth $10.7M.
- Foresite Capital Management IV's largest Q1 2019 buy was Alector: 1,203,462 shares worth $10.7M.
- Foresite Capital Management IV added most to Cytokinetics in Q1 2019, an estimated $11.4M increase.
- Foresite Capital Management IV's biggest Q1 2019 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $14.6M.
- Foresite Capital Management IV fully exited Orchard Therapeutics plc American Depositary Shares in Q1 2019, selling an estimated $10.5M.
- Foresite Capital Management IV's ten largest holdings make up 88% of its $278M portfolio in Q1 2019.
- Foresite Capital Management IV opened 2 new positions and closed 4 in Q1 2019.
- Foresite Capital Management IV's portfolio value rose 28% quarter-over-quarter to $278M.
Based on Foresite Capital Management IV's 13F filing for Q1 2019, filed 14 May 2019.